530135-29-6

Upstream product

• 5326-34-1 4-Bromo-3-nitrotoluene 
• 637-89-8 4-sulfanylphenol 
• 195455-54-0 trifluoromethanesulfonic acid 4-methyl-2-nitrophenyl ester 
• 57076-51-4 2-Nitro-4-methylphenyl-trifluoracetat 
• 119-33-5 4-methyl-2-nitrophenol 
• 4288-90-8 2-nitro-4-toluenylsulfenyl chloride 
• 108-95-2 phenol 

Downstream Products

• 944503-59-7 4-[4-methyl-2-(7-methyl-pyrido[2,3-d]pyrimidin-4-ylamino)-phenylsulfanyl]-phenol 
• 1365921-19-2 C₂₂H₂₀N₄OS 
• 944504-13-6 C₂₃H₂₂N₄OS 
• 944503-77-9 C₂₃H₂₂N₄OS 
• 944503-98-4 C₂₃H₂₀N₄OS 
• 944504-63-6 C₂₁H₁₉N₅OS₂ 
• 1365922-39-9 C₂₀H₁₇N₅O₂S 

Relevant academic research and scientific papers

Novel Hepatitis C virus replicon inhibitors: Synthesis and structure-activity relationships of fused pyrimidine derivatives

The synthesis of several pyrido[2,3-d]pyrimidine and pyrimido[4,5-d] pyrimidine analogs is described with one such analog possessing subnanomolar potency in both genotype 1a and 1b cell culture HCV replicon assays.

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ( HCV ) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, coformulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Nitrophenyl derivatives as aldose reductase inhibitors

Nitrophenyl derivatives were recently discovered as a new class of ALR2 inhibitors by means of docking and database screening of the National Cancer Institute database of organic molecules. The nitro group was predicted to bind to the Tyr48 and His110 act